{"disease":{"id":"rsv","name":"rsv"},"drugs":{"marketed":[{"drug_id":"nirsevimab","indication_name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Beyfortus","generic_name":"NIRSEVIMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"RSV","drug_class":"Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]","quality_score":10,"revenue":"800","mechanism":"BEYFORTUS is a monoclonal antibody that targets RSV."},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain chronic lung conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain heart conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"beyfortus","indication_name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Beyfortus","company_name":"National Institute of Allergy and Infectious Diseases (NIAID)","drug_phase":"marketed","molecular_target":"Fusion glycoprotein F0","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"rsvpref-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV-associated hospitalization due to prematurity.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF Vaccine","generic_name":"rsvpref-vaccine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"RSV","drug_class":"vaccine","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"rsvpref-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in young children with a history of premature birth or bronchopulmonary dysplasia.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF Vaccine","generic_name":"rsvpref-vaccine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"RSV","drug_class":"vaccine","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"rsvpref-mdv","indication_name":"Prevention of RSV lower respiratory tract disease in neonates at high risk of RSV disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF MDV","generic_name":"rsvpref-mdv","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"RSV F protein","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"rsvpref-mdv","indication_name":"Prevention of RSV lower respiratory tract disease in infants and children at high risk of RSV disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF MDV","generic_name":"rsvpref-mdv","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"RSV F protein","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"nirsevimab-alip","indication_name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BEYFORTUS","generic_name":"NIRSEVIMAB-ALIP","company_name":"ASTRAZENECA AB","drug_phase":"marketed","molecular_target":"Fusion glycoprotein F0","drug_class":"Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"rsvpref","indication_name":"Prevention of RSV lower respiratory tract disease in neonates at high risk of RSV disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF","generic_name":"rsvpref","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"RSV F protein","drug_class":"Monoclonal antibody","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"rsvpref","indication_name":"Prevention of RSV lower respiratory tract disease in infants and children at high risk of RSV disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF","generic_name":"rsvpref","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"RSV F protein","drug_class":"Monoclonal antibody","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"rsv-prefusion-f-protein-based-vaccine","indication_name":"Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSV prefusion F protein-based vaccine","generic_name":"rsv-prefusion-f-protein-based-vaccine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Respiratory syncytial virus fusion (F) protein","drug_class":"Viral protein subunit vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"rsvpref-120-g","indication_name":"Prevention of RSV lower respiratory tract disease in neonates at high risk of RSV disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF 120 µg","generic_name":"rsvpref-120-g","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Prefusion form of the RSV F protein","drug_class":"Recombinant subunit vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to prematurity.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"rsvpref-120-g","indication_name":"Prevention of RSV lower respiratory tract disease in infants and children at high risk of RSV disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF 120 µg","generic_name":"rsvpref-120-g","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Prefusion form of the RSV F protein","drug_class":"Recombinant subunit vaccine","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":15,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05622331","title":"Burden of Respiratory Syncytial Virus (RSV) in Children in Sweden (BRICS): A Retrospective Study in Sweden","phase":"","overall_status":"COMPLETED","enrollment_count":1100000,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT06160128","title":"Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)","phase":"","overall_status":"RECRUITING","enrollment_count":400000,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT06511687","title":"Effectiveness And Impact Of Nirsevimab In Chile (NIRSE-CL)","phase":"","overall_status":"RECRUITING","enrollment_count":160000,"lead_sponsor_name":"Instituto Sistemas Complejos de Ingeniería","has_results":false},{"nct_id":"NCT06180993","title":"Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization","phase":"","overall_status":"RECRUITING","enrollment_count":42000,"lead_sponsor_name":"Federico Martinón Torres","has_results":false},{"nct_id":"NCT07249320","title":"Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":39456,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07272434","title":"Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"MAXVAX Biotechnology Limited Liability Company","has_results":false},{"nct_id":"NCT07147517","title":"Preparedness Through Respiratory Virus Epidemiology and Community Engagement","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"University of California, San Diego","has_results":false},{"nct_id":"NCT06207929","title":"Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections","phase":"","overall_status":"COMPLETED","enrollment_count":18157,"lead_sponsor_name":"Evidation Health","has_results":false},{"nct_id":"NCT06229444","title":"Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to ILI","phase":"NA","overall_status":"COMPLETED","enrollment_count":17043,"lead_sponsor_name":"Evidation Health","has_results":false},{"nct_id":"NCT06955728","title":"A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respiratory Tract Infection When the Pregnant Woman Receives the Approved RSV Vaccine Compared to a Placebo.","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":13000,"lead_sponsor_name":"University of Witwatersrand, South Africa","has_results":false},{"nct_id":"NCT03627572","title":"RESCEU Study: Defining the Burden of Disease of Respiratory Syncytial Virus in Europe in Infants","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT07321314","title":"RSV Burden in Hong Kong","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT05767294","title":"Epidemiological and Clinical Characteristics of Hospitalized Patients Under 5 Years Old With RSV Infection in Central China, Wuhan","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT05437510","title":"Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":8057,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT06252285","title":"Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":6300,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT07445763","title":"TARSILA Real-World Evidence Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Inova Medical","has_results":false},{"nct_id":"NCT06185647","title":"Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis","phase":"","overall_status":"COMPLETED","enrollment_count":4924,"lead_sponsor_name":"Hôpital Armand Trousseau","has_results":false},{"nct_id":"NCT06993753","title":"Duration of Protection of Nirsevimab Against Hospitalisation for Respiratory Syncytial Virus Infection","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4350,"lead_sponsor_name":"Griffith University","has_results":false},{"nct_id":"NCT06172660","title":"Real-World Effectiveness of Perinatal RSV Immunoprophylaxis","phase":"","overall_status":"RECRUITING","enrollment_count":3750,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT05913700","title":"Effect of Respiratory Virus Infection on EmeRgencY Admission Study (EVERY Study)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3067,"lead_sponsor_name":"Institute for Clinical Effectiveness, Japan","has_results":false},{"nct_id":"NCT07164430","title":"The Impact of the 2025 Infant and Maternal Respiratory Syncytial Virus (RSV) Prevention Program on RSV-related Hospitalisations in the Australian Capital Territory","phase":"","overall_status":"COMPLETED","enrollment_count":2792,"lead_sponsor_name":"Nicola Irwin","has_results":false},{"nct_id":"NCT05928507","title":"FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"Baebies, Inc.","has_results":false},{"nct_id":"NCT04782336","title":"Sample Collection Study to Aid Evaluation of an Influenza A/B, Respiratory Syncytial Virus & COVID-19 Virus POC Test","phase":"NA","overall_status":"SUSPENDED","enrollment_count":2500,"lead_sponsor_name":"LumiraDx UK Limited","has_results":false},{"nct_id":"NCT07177508","title":"First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory","phase":"","overall_status":"COMPLETED","enrollment_count":2355,"lead_sponsor_name":"Nicola Irwin","has_results":false},{"nct_id":"NCT06397768","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":2226,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT06521944","title":"RSV Vaccine Pregnancy Registry","phase":"","overall_status":"RECRUITING","enrollment_count":2062,"lead_sponsor_name":"CorEvitas","has_results":false},{"nct_id":"NCT07217639","title":"Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Aptitude Medical Systems","has_results":false},{"nct_id":"NCT03698084","title":"RESCEU: Defining the Burden of RSV Disease","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT05727202","title":"Project STARFISH - PRJ0002679","phase":"","overall_status":"COMPLETED","enrollment_count":1909,"lead_sponsor_name":"Thermo Fisher Scientific, Inc","has_results":false},{"nct_id":"NCT04743609","title":"RSV Burden in Outpatient and Hospital Settings","phase":"NA","overall_status":"RECRUITING","enrollment_count":1900,"lead_sponsor_name":"Association Clinique Thérapeutique Infantile du val de Marne","has_results":false},{"nct_id":"NCT06008457","title":"Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit","phase":"","overall_status":"COMPLETED","enrollment_count":1600,"lead_sponsor_name":"Sequenom, Inc.","has_results":false},{"nct_id":"NCT06689423","title":"Clinical Evaluation of the VitaSIRO Solo™ Respiratory Assay","phase":"","overall_status":"COMPLETED","enrollment_count":1268,"lead_sponsor_name":"Credo Diagnostics Biomedical Pte. Ltd.","has_results":false},{"nct_id":"NCT05277298","title":"Household Study of COVID-19, Influenza and RSV Burden, Transmission Dynamics and Viral Interaction in South Africa","phase":"","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"National Institute for Communicable Diseases, South Africa","has_results":false},{"nct_id":"NCT07308158","title":"Covid Flu A/B and RSV 4 in 1 Diagnostic Test","phase":"","overall_status":"COMPLETED","enrollment_count":1119,"lead_sponsor_name":"iHealth Labs inc","has_results":false},{"nct_id":"NCT07264478","title":"Diagnosis and Treatment Status and Medical Burden of Respiratory Syncytial Virus Infection in Children in China","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1100,"lead_sponsor_name":"Beijing Children's Hospital","has_results":false},{"nct_id":"NCT03621930","title":"RESCEU Study, Defining the Burden of Disease of RSV in Older Adults","phase":"","overall_status":"UNKNOWN","enrollment_count":1040,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT05096208","title":"Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1028,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04938830","title":"Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1003,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06392451","title":"LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"DiaSorin Molecular LLC","has_results":false},{"nct_id":"NCT06705140","title":"A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":947,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT05842967","title":"A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":885,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07382219","title":"Real-World Effectiveness of Nirsevimab Against RSV-Related and All-Cause Respiratory Tract Infections in Chinese Infants","phase":"","overall_status":"COMPLETED","enrollment_count":816,"lead_sponsor_name":"Han Tongyan","has_results":false},{"nct_id":"NCT06401720","title":"Age Related Differences in Respiratory Immune Responses in Influenza Virus Infection","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":800,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT06286007","title":"Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control","phase":"","overall_status":"RECRUITING","enrollment_count":784,"lead_sponsor_name":"Hospital Clinico Universitario de Santiago","has_results":false},{"nct_id":"NCT05268939","title":"Performance Evaluation of the LumiraDx SARS-CoV-2 & FLU A/B and SARS-CoV-2 & RSV Tests for Aid in the Assessment of COVID-19","phase":"NA","overall_status":"COMPLETED","enrollment_count":668,"lead_sponsor_name":"LumiraDx UK Limited","has_results":false},{"nct_id":"NCT04944160","title":"Impact of the Covid-19 on Respiratory Syncytial Virus (RSV) Epidemic","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT07516418","title":"Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":570,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06866405","title":"A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":550,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06890416","title":"A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":526,"lead_sponsor_name":"Pfizer","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}